

## Recession Proof Companies: Norgine

With 22 consecutive years of growth under its belt, Norgine is still going from strength to strength. Norgine's CEO Peter Stein talks to *Pharmaceutical Executive Europe* about the secret of its success

Click here

[http://digital.findpharma.com//nxtbooks/advanstaruk/pee\\_digest\\_20090805/index.php?startid=10#/10/OnePage](http://digital.findpharma.com//nxtbooks/advanstaruk/pee_digest_20090805/index.php?startid=10#/10/OnePage) to access the latest edition of *Pharmaceutical Executive Europe* and read Peter's interview

### Notes to editor

Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2008 Norgine's sales were €238 million, the 22<sup>nd</sup> year of double-digit growth at constant exchange rates. The company employs over 1,000 people many of whom work in the sales, marketing and manufacturing functions.

Norgine's current focus is pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP a new generation of bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

Norgine's web site [www.norgine.com](http://www.norgine.com)

For further information, please contact:

Julie Hornby Winfield. Global Corporate Communications Manager

T: +44 (0)1895 826642

E: [jhornbywinfield@norgine.com](mailto:jhornbywinfield@norgine.com)